These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 7714099)
1. Activation of T lymphocyte subsets by synthetic TSH receptor peptides and recombinant glutamate decarboxylase in autoimmune thyroid disease and insulin-dependent diabetes. Mukuta T; Yoshikawa N; Arreaza G; Resetkova E; Leushner J; Song YH; Akasu F; Onaya T; Volpé R J Clin Endocrinol Metab; 1995 Apr; 80(4):1264-72. PubMed ID: 7714099 [TBL] [Abstract][Full Text] [Related]
2. Activation of CD8+ T lymphocytes in insulin-dependent diabetes mellitus. Togun RA; Resetkova E; Kawai K; Enomoto T; Volpé R Clin Immunol Immunopathol; 1997 Mar; 82(3):243-9. PubMed ID: 9073547 [TBL] [Abstract][Full Text] [Related]
3. T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain. Soliman M; Kaplan E; Yanagawa T; Hidaka Y; Fisfalen ME; DeGroot LJ J Clin Endocrinol Metab; 1995 Mar; 80(3):905-14. PubMed ID: 7533773 [TBL] [Abstract][Full Text] [Related]
4. The effect of interleukin-2 on suppressor T lymphocytes in autoimmune thyroid disease. Yoshikawa N; Morita T; Arreaza G; Resetkova E; Mukuta T; Volpé R Clin Invest Med; 1995 Apr; 18(2):91-8. PubMed ID: 7788961 [TBL] [Abstract][Full Text] [Related]
5. Studies of CD4+ (helper/inducer) T lymphocytes in autoimmune thyroid disease: demonstration of specific induction in response to thyroid peroxidase (TPO) in vitro and its relationship with thyroid status in vivo. Akasu F; Kasuga Y; Matsubayashi S; Carayon P; Volpé R Thyroid; 1991; 1(3):215-22. PubMed ID: 1688100 [TBL] [Abstract][Full Text] [Related]
6. Reduced activation of suppressor T lymphocytes by specific antigens in autoimmune thyroid disease. Yoshikawa N; Morita T; Resetkova E; Arreanza G; Carayon P; Volpé R J Endocrinol Invest; 1993 Sep; 16(8):609-17. PubMed ID: 8258649 [TBL] [Abstract][Full Text] [Related]
7. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases? Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112 [TBL] [Abstract][Full Text] [Related]
8. Proliferative responses of peripheral blood mononuclear cells from patients with Graves' disease to synthetic peptides epitopes of human thyrotropin receptor. Okamoto Y; Yanagawa T; Fisfalen ME; DeGroot LJ Thyroid; 1994; 4(1):37-42. PubMed ID: 7519915 [TBL] [Abstract][Full Text] [Related]
9. Study of induction of activation of human peripheral blood mononuclear cells with a non-activating form of anti-CD3 MoAb in autoimmune thyroid disease (AITD). Resetkova E; Arreaza G; Yoshikawa N; Morita T; Kim H; Carayon P; Volpé R Clin Exp Immunol; 1993 Mar; 91(3):397-403. PubMed ID: 8443962 [TBL] [Abstract][Full Text] [Related]
10. Patterns of cellular immune responses to thyrocyte membrane antigens and specific immunoregulatory defects in autoimmune thyroid disease. O'Brien CJ; Macchia E; Cundy TF; Concetti R; McSorley CG; MacFarlane IG; Vento S; Eddleston AL J Clin Lab Immunol; 1990 Jul; 32(3):103-8. PubMed ID: 1966945 [TBL] [Abstract][Full Text] [Related]
11. Induction of oral tolerance in human autoimmune thyroid disease. Lee S; Scherberg N; DeGroot LJ Thyroid; 1998 Mar; 8(3):229-34. PubMed ID: 9545109 [TBL] [Abstract][Full Text] [Related]
12. T-cell reactivity to recombinant human thyrotropin receptor extracellular domain and thyroglobulin in patients with autoimmune and nonautoimmune thyroid diseases. Soliman M; Kaplan E; Fisfalen ME; Okamoto Y; DeGroot LJ J Clin Endocrinol Metab; 1995 Jan; 80(1):206-13. PubMed ID: 7829613 [TBL] [Abstract][Full Text] [Related]
15. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls. Kristensen B Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836805 [TBL] [Abstract][Full Text] [Related]
16. T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects. Schloot NC; Roep BO; Wegmann DR; Yu L; Wang TB; Eisenbarth GS Diabetologia; 1997 Mar; 40(3):332-8. PubMed ID: 9084973 [TBL] [Abstract][Full Text] [Related]
17. Heterogeneity in cellular and antibody responses against thyrotropin receptor in patients with Graves' disease detected using synthetic peptides. Fan JL; Desai RK; Seetharamaiah GS; Dallas JS; Wagle NM; Prabhakar BS J Autoimmun; 1993 Dec; 6(6):799-808. PubMed ID: 7512341 [TBL] [Abstract][Full Text] [Related]
18. Evidence for cell-mediated immunity and specific suppressor T lymphocyte dysfunction in Graves' disease and diabetes mellitus. Topliss D; How J; Lewis M; Row V; Volpé R J Clin Endocrinol Metab; 1983 Oct; 57(4):700-5. PubMed ID: 6224805 [TBL] [Abstract][Full Text] [Related]
19. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. Inaba H; Martin W; De Groot AS; Qin S; De Groot LJ J Clin Endocrinol Metab; 2006 Jun; 91(6):2286-94. PubMed ID: 16595602 [TBL] [Abstract][Full Text] [Related]